BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 17707884)

  • 1. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
    Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
    Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
    Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC
    Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
    Mercier F; Monczak Y; François M; Prchal J; Galipeau J
    Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
    Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
    Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
    Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
    Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis!
    Fraga GR; Caughron SK
    Am J Dermatopathol; 2010 Oct; 32(7):727-30. PubMed ID: 20859081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders.
    Lieu CH; Wu HS; Hon YC; Tsai WH; Yang CF; Wang CC; Lin YC; Shih CH; Hsu HC
    Intern Med J; 2008 Jun; 38(6):422-6. PubMed ID: 18336541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis.
    Murugesan G; Aboudola S; Szpurka H; Verbic MA; Maciejewski JP; Tubbs RR; Hsi ED
    Am J Clin Pathol; 2006 Apr; 125(4):625-33. PubMed ID: 16627272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders.
    Chen S; Fei H; Zhang R; Xue Y; Pan J; Wu Y; Ceng J
    Am J Hematol; 2007 Jun; 82(6):458-9. PubMed ID: 17266061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.
    Pich A; Riera L; Sismondi F; Godio L; Davico Bonino L; Marmont F; Francia di Celle P
    J Clin Pathol; 2009 Sep; 62(9):798-801. PubMed ID: 19734476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.